PCN140 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VS CRIZOTINIB IN FIRST LINE ANAPLASTIC LYMPHOMA KINASE POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN PORTUGAL
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.223
https://www.valueinhealthjournal.com/article/S1098-3015(18)33523-X/fulltext
Title :
PCN140 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VS CRIZOTINIB IN FIRST LINE ANAPLASTIC LYMPHOMA KINASE POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN PORTUGAL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33523-X&doi=10.1016/j.jval.2018.09.223
First page :
Section Title :
Open access? :
No
Section Order :
1614